

29 January 2024

### DESPATCH OF RIGHTS ISSUE OFFER MATERIALS

HeraMED Limited (ASX:HMD) (**the Company**) is pleased to advise that the offer booklet released to ASX on 18 January 2024 (**Offer Booklet**) and the entitlement and acceptance form (or a letter advising where to access those documents) for the non-renounceable pro-rata entitlement issue of 1 new Share for every 5 existing Shares held by Eligible Shareholders on the Record Date, at an issue price of \$0.02 per New Share to raise up to approximately \$1.28 million (before costs) (**Entitlement Offer**) were dispatched to eligible shareholders today, 29 January 2024. The letter sent to eligible shareholders is enclosed with this announcement.

Notifications have also been sent to shareholders who are ineligible to participate in the Entitlement Offer in accordance with Listing Rule 7.7.1(b).

For further information please contact the Company at the details below.

--ENDS--

Authorised by the Board of HeraMED Limited.

For more information please contact:

**HeraMED Limited**  
Executive Chairman  
Dr Ron Weinberger  
M: +61 406 384 189  
E: [ron@hera-med.com](mailto:ron@hera-med.com)

**Company Secretary**  
Jonathan Hart  
E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Investor Relations**  
Tim Chapman  
T: +61 419 897 062  
E: [tchapman@claritycap.com.au](mailto:tchapman@claritycap.com.au)

#### **About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

-ENDS-

29 January 2024

[EntityRegistrationDetailsLine1Envelope]  
[EntityRegistrationDetailsLine2Envelope]  
[EntityRegistrationDetailsLine3Envelope]  
[EntityRegistrationDetailsLine4Envelope]  
[EntityRegistrationDetailsLine5Envelope]  
[EntityRegistrationDetailsLine6Envelope]

### **NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES**

Dear Shareholder

#### **HERAMED LIMITED ENTITLEMENT OFFER - NOTIFICATION TO ELIGIBLE SHAREHOLDERS**

We write to you as the registered holder of fully paid ordinary shares in HeraMED Limited (the **Company** or **HeraMED**) as at 7.00pm (Sydney time) on Tuesday, 23 January 2024 (**Record Date**).

#### **Key Features of the Entitlement Offer**

Pursuant to the rights issue offer booklet released to ASX on 18 January 2024 (**Offer Booklet**), the Company is undertaking a non-renounceable pro-rata entitlement issue of 1 new Share for every 5 existing Shares held by Eligible Shareholders on the Record Date, at an issue price of \$0.02 per New Share to raise up to approximately \$1.28 million (before costs) (**Entitlement Offer**) on the terms described in the Offer Booklet.

Eligible Shareholders who subscribe for their entitlement in full may also apply for additional New Shares in excess of their entitlement pursuant to the Shortfall described in the Offer Booklet.

#### **How to Access the Offer Booklet and a personalised Application Form:**

1. **ONLINE** - The Offer Booklet and personalised Application Form can be accessed via the Automic Investor portal: <https://investor.automic.com.au/#/home>
2. **PAPER** - Request a paper copy of the Offer Booklet and the personalised Application Form by contacting the Company's Share Registry on 1300 288 664 (within Australia) and +61 2 9698 5414 (outside Australia).

Details of the Entitlement Offer are contained in the Offer Booklet. The Offer Booklet can be accessed from the ASX and Company websites [www.asx.com.au](http://www.asx.com.au) and <https://www.hera-med.com/investor-relations> respectively.

### Indicative Entitlement Offer Timetable

An indicative timetable for the Entitlement Offer is below\*:

Release of Appendix 3B for the Offer Release of section 708AA cleansing notice Announcement of Offer Booklet	18 January 2024
Ex-Date	22 January 2024
Record Date (7.00pm Sydney time)	23 January 2024
HeraMED send Offer Booklet and personalised entitlement and acceptance forms to Eligible Shareholders and announces this has occurred Offer opening date	29 January 2024
Last day to extend the Closing Date	2 February 2024
Closing Date (5.00pm Sydney time)	7 February 2024
Unless otherwise determined by ASX, New Shares quoted on a deferred settlement basis from market open	8 February 2024
Last day for HeraMED to announce results of the Offer, issue New Shares taken up under the Offer and to lodge an Appendix 2A with ASX to notify ASX of the issue of New Shares and apply for their quotation (Before noon (Sydney time))	14 February 2024

*\*The dates above are indicative only and subject to change. Subject to the Corporations Act and ASX Listing Rules, HeraMED reserves the right to amend this indicative timetable by making an announcement to ASX. In particular HeraMED reserves the right to extend the Closing Date or withdraw the offer without notice by making an announcement to ASX. Any extension of the Closing Date will have a consequential effect on the anticipated date for the issue of New Shares under the Offer.*

It is important that you read the Offer Booklet carefully before deciding whether to participate in the Entitlement Offer and seek advice from your suitably qualified professional adviser if you have any queries. This notice is to inform you of the Entitlement Offer. You are not required to do anything in respect to this letter.

### General Enquires

For all general shareholder enquiries, please contact the Company's Share Registry on 1300 288 664 (within Australia) and +61 2 9698 5414 (outside Australia).

You should also consult your stockbroker, solicitor, accountant or other suitably qualified professional adviser to evaluate whether or not to participate in the Entitlement Offer.



On behalf of the Board and management of HeraMED, thank you for your continued support of HeraMED.

--ENDS--

Authorised by the Board of HeraMED Limited.

For more information please contact:

**HeraMED Limited**

Executive Chairman

Dr Ron Weinberger

M: +61 406 384 189

E: [ron@hera-med.com](mailto:ron@hera-med.com)

**Company Secretary**

Jonathan Hart

E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Investor Relations**

Tim Chapman

T: +61 419 897 062

E: [tchapman@claritycap.com.au](mailto:tchapman@claritycap.com.au)

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

**-ENDS-**